Original from: Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the ¡°Company¡± or ¡°Burning Rock¡±) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.
The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib¨Cfulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib¨Cfulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.
In the study, Burning Rock's flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China. We are proud to have supported our pharma client in such a high impact study, after a rigorous test solution provider evaluation process.
https://www.nejm.org/doi/full/10.1056/NEJMoa2214131
